Curis | CRIS - Assets


Curis reported $29.69M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Alaunos Therapeutics USD 1.52M 367K Jun/2026
Amgen USD 96.05B 409M Sep/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
Bayer EUR 113.47B 6.18B Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
CSL USD 37.9B 1.5B Dec/2025
Curis USD 29.69M 9.72M Mar/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Exelixis USD 2.51B 19.26M Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 130.29B 1.23B Sep/2026
Takeda JPY 15.27T 391.77B Sep/2026
TG Therapeutics USD 1.64B 110.79M Jun/2026
Verastem USD 227.81M 18.63M Mar/2026